Shares of Myomo, Inc. (NASDAQ:MYO) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Analysts have set a 1-year consensus target price of $3.00 for the company and are anticipating that the company will post ($0.16) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Myomo an industry rank of 153 out of 256 based on the ratings given to related companies.

Separately, Roth Capital reiterated a “buy” rating on shares of Myomo in a research report on Tuesday, February 5th.

MYO stock traded down $0.05 during trading on Friday, reaching $1.06. 54,791 shares of the company’s stock were exchanged, compared to its average volume of 95,208. Myomo has a 1-year low of $1.10 and a 1-year high of $3.79.

Myomo (NASDAQ:MYO) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.01. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $0.70 million.

About Myomo

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Featured Story: Systematic Risk and Investors

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with's FREE daily email newsletter.